Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Rectal cancer, drawn from the whole corpus: 20 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No validated test predicts which clinical complete responders will regrow under watch and wait.
Long-term bowel, sexual and urinary function after total neoadjuvant therapy is poorly measured.
Whether circulating tumour DNA can safely guide surveillance after organ preservation is untested in randomised trials.
Lateral pelvic node disease is managed differently in Japan and the West with no comparative trial.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.
A milestone in how this cancer is treated.
Breakthrough Therapy designation, dMMR locally advanced rectal cancer (organ preservation)
5-year disease-free survival 80.
A milestone in how this cancer is treated.